Trial Profile
Phase II Study of the combination of Elotuzumab with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Elotuzumab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Mar 2024 Planned End Date changed from 30 Apr 2024 to 30 Apr 2025.
- 01 Mar 2024 Planned primary completion date changed from 30 Apr 2024 to 30 Apr 2025.
- 08 Dec 2020 Results (n=100) presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology